跳转至内容
Merck
CN

V900324

甲氨蝶呤 水合物

Vetec, reagent grade, 98%

别名:

对-[(2,4-二氨基喋啶-6)-N-甲基甲氨基]苯甲酰谷氨酸 水合物, L-氨甲喋呤 水合物, MTX 水合物, 氟安定 水合物, 氨甲叶酸 水合物, 氨甲喋呤 水合物

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C20H22N8O5 · xH2O
化学文摘社编号:
分子量:
454.44 (anhydrous basis)
UNSPSC Code:
12352202
PubChem Substance ID:
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C20H22N8O5.H2O/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30;/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27);1H2/t13-;/m0./s1

InChI key

FPJYMUQSRFJSEW-ZOWNYOTGSA-N

grade

reagent grade

product line

Vetec

assay

98%

storage temp.

−20°C

Gene Information

human ... DHFR(1719)

正在寻找类似产品? 访问 产品对比指南

Application

二氢叶酸还原酶的有效抑制剂 和抗肿瘤的研究试剂。 用于抑制二氢叶酸还原酶在DHFR蛋白表达系统中的表达。
二氢叶酸还原酶的有效抑制剂 和抗肿瘤的研究试剂。 用于抑制二氢叶酸还原酶在DHFR蛋白表达系统中的表达。也显示免疫抑制作用,如类风湿关节炎。
二氢叶酸还原酶的有效抑制剂 和抗肿瘤的研究试剂。 用于抑制二氢叶酸还原酶在DHFR蛋白表达系统中的表达。还可有效治疗耐甲氧嘧啶的 间日 疟原虫。

Legal Information

Vetec is a trademark of Merck KGaA, Darmstadt, Germany

pictograms

Skull and crossbonesHealth hazard

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Josef Singer et al.
Molecular cancer therapeutics, 13(7), 1777-1790 (2014-04-24)
Passive immunotherapy with monoclonal antibodies represents a cornerstone of human anticancer therapies, but has not been established in veterinary medicine yet. As the tumor-associated antigen EGFR (ErbB-1) is highly conserved between humans and dogs, and considering the effectiveness of the
Methotrexate: new uses for an old drug.
Philip J Hashkes et al.
The Journal of pediatrics, 164(2), 231-236 (2013-11-30)
Ian Joseph Cohen et al.
Pediatric blood & cancer, 61(1), 7-10 (2013-09-17)
To determine the optimal time of folinic acid rescue after methotrexate (MTX) treatment in patients with ALL, we selected and evaluated relevant studies that included doses, rescue delay, and side effects. Rescue at 42-48 hours resulted in considerable toxicity, except
Johanna P Cremers et al.
Current opinion in pulmonary medicine, 19(5), 545-561 (2013-07-25)
Although glucocorticosteroids are considered the first-line treatment in sarcoidosis, refractory cases require alternatives, such as methotrexate (MTX). The aim of this study was to develop, on behalf of the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG), multinational evidence-based
Daniel H Solomon et al.
The American journal of medicine, 126(8), 730-730 (2013-07-28)
Elevated tumor necrosis factor (TNF)-α likely contributes to the excess cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in rheumatoid arthritis patients starting a TNF-α blocking agent versus a nonbiologic disease-modifying antirheumatic drug (nbDMARD). Subjects with rheumatoid

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持